Back to News
Sep 25, 2025 8:00 AM

Drugs Made In America Acquisition II Corp. Announces Pricing of $500,000,000 Initial Public Offering

Fort Lauderdale, FL, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIU) (the "Company") announced today the pricing yesterday of its initial public offering of 50,000,000 units at $10.00 per unit. The units are expected to be listed on The Nasdaq Global Market ("Nasdaq") and trade under the ticker symbol "DMIIU" beginning September 25, 2025. Each unit consists of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the ordinary shares and rights are expected to be listed on Nasdaq under the symbols "DMII" and "DMIIR," respectively. The underwriters have been granted a 45-day option to purchase up to an additional 7,500,000 units offered by the Company to cover over-allotments, if any. The offering is expected to close on September 26, 2025, subject to customary closing conditions.

Cantor Fitzgerald & Co. is acting as the sole book-running manager in the offering. Loeb & Loeb LLP is serving as legal counsel to the Company. Ellenoff Grossman & Schole LLP is serving as legal counsel to Cantor Fitzgerald & Co.

A registration statement on Form S-1 (333-288791) relating to these ...